Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.

Abstract

To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer3
ISSN0954-6634
StatusVeröffentlicht - 2011
pubmed 21254886